Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03402607 · ClinicalTrials.gov registry record · NA
Trial Comparing PLA to HIGRT (PROVE-HCC)
A NA study, sponsored by Duke University.
- Terminated
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT03402607 is a NA study that was terminated before completion, run by Duke University. The registered enrollment target is 12 participants.
The verdict
NCT03402607, a NA study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase II, randomized trial compare Quality of Life for patients with Hepatocellular Carcinoma (HCC) who are not surgical candidates or decline surgery and are treated with Percutaneous Local Ablation (PLA) or Hypofractionated Image-Guided Radiation Therapy (HIGRT).
Interventions
- PROCEDURE Percutaneous Local Ablation
- RADIATION Hypofractionated Image Guided Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-08-08 |
| Est. Completion | 2020-03-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03402607
The ClinicalTrials.gov registry entry for NCT03402607 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Percutaneous Local Ablation is the first listed.
NCT03402607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03402607 about?
NCT03402607 is a clinical study titled "Trial Comparing PLA to HIGRT (PROVE-HCC)". This phase II, randomized trial compare Quality of Life for patients with Hepatocellular Carcinoma (HCC) who are not surgical candidates or decline surgery and are treated with Percutaneous Local Ablation (PLA) or Hypofractionated Image-Guided Radiation Therapy (HIGRT).
What is the current status of trial NCT03402607?
This trial is currently terminated. It is a NA study. The enrollment target is 12 participants. The study started on 2018-08-08. Estimated completion is 2020-03-25.
What interventions are being tested in trial NCT03402607?
The interventions under investigation include: Percutaneous Local Ablation (PROCEDURE), Hypofractionated Image Guided Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03402607?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.